Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda plus Taxotere with or without Herceptin in Neoadjuvant Breast Cancer
NCT00127933Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2005
- Primary completion
- Apr 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Pathological Complete Response Plus Near Complete Response. Started Aug 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00127933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127933.